Various studies in the last years have shown that using SRM/MRM has the potential to identify hundreds of biomarker candidates in one study (Mermelekas, 2015). However, panel development remains asignificant bottleneck in the adoption of targeted proteomics.

At Biognosys, we believe that we can dramatically improve human health by deciphering the biological complexity of diseases. By providing access to the proteome on all levels, we enable life science researchers and drug hunters to unlock true discoveries.

We push the boundaries of what is possible with our proteomics solutions to help usher in a new age of bioengineering and precision medicine.

When we look at the proteome differently, we envision a better world!

To learn more about our vision, mission, and values, watch our new corporate video and visit: biognosys.com/our-story/

German life sciences magazine Transkript Laborwelt interviewed our Chief Business Officer Kristina Beeler, Ph.D., about the emerging wave of precision proteomics.

Read Full Magazine Issue (German language only)

The brochure provides an overview of the key features and benefits of our next-generation TrueSignature^® platform. In addition, it elaborates on the specificities of our customizable panels for clinical and pharmacodynamics studies.

Download Brochure

New: Spectronaut^® 19

Unlock Your Data's True Story

New: Spectronaut^® 19

Unlock Your Data's True Story

Learn More